Thursday, Johnson & Johnson (NYSE:JNJ) released topline data from the pivotal Phase 3 GRAVITI investigational study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn’s disease. The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission and endoscopic response at Week 12. All remaining multiplicity-controlled secondary endpoints at Week 12, Week 24 and Week 48 were statistically significant compared to placebo. Also Read: Johnson ...